Key result
Dabigatran at 110 mg/day caused no serious adverse effects such as major bleeding or stroke in elderly patients over 80 years of age with atrial fibrillation, though two patients discontinued due to APTT prolongation.
Why the study?
Does dabigatran 220 mg/day cause serious adverse effects in elderly patients ≥80 years of age with atrial fibrillation?
Observational (n=28)
No
Does dabigatran 220 mg/day cause serious adverse effects in elderly patients ≥80 years of age with atrial fibrillation?
Dabigatran 220 mg/day appears to be tolerated without serious bleeding complications in a small cohort of elderly patients ≥80 years with atrial fibrillation, though APTT monitoring may be necessary.
No takes yet. Share an insight, caveat, or question.
Dabigatran 110 mg showed no major events in very elderly AF; leaves open safety confirmation and optimal dosing in randomized trials.
Kono et al. (2014) conducted an observational in Atrial fibrillation (n=28). Dabigatran vs. Warfarin was evaluated on Incidence of serious adverse effects (major bleeding or stroke). Dabigatran at 110 mg/day caused no serious adverse effects such as major bleeding or stroke in elderly patients over 80 years of age with atrial fibrillation, though two patients discontinued due to APTT prolongation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: